文献速递妇产影像儿科影像心血管US

母亲补充二十二碳六烯酸不会导致胎儿动脉导管收缩:随机对照试验

Maternal supplementation with docosahexaenoic acid does not cause constriction of fetal ductus arteriosus: randomized controlled trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-01-01

这项双盲随机对照试验在2018至2021年纳入孕27-28周、胎儿正常且无心脏/心外异常或导管收缩的孕妇,干预组口服450 mg/天DHA共8周,安慰剂组口服大豆卵磷脂胶囊共8周。结果显示两组母血清PGE2水平及导管血流多普勒超声心动图参数均无显著差异,未观察到动脉导管收缩病例。

要点

  • 孕晚期按临床推荐剂量补充DHA未导致母血清PGE2抑制或胎儿动脉导管收缩。
  • 随访8周后干预组与安慰剂组PGE2及导管血流多普勒参数无显著差异。
  • 研究期间未观察到任何动脉导管收缩病例。

核心结论

  • 孕晚期按临床推荐剂量补充DHA未导致PGE2抑制或动脉导管收缩,但作者认为需在更大样本量的上市后监测研究中确认,以检验DHA的完整安全性特征。

研究设计与样本

  • 双盲、平行组随机对照试验,2018至2021年开展,每组24例;干预组口服含450 mg/天DHA的omega-3补充剂8周,安慰剂组口服大豆卵磷脂胶囊8周;在基线和随访时行胎儿形态超声、胎儿多普勒超声心动图及血样采集,比较两组间及基线与随访间的PGE2水平和超声心动图参数。

关键影像表现/征象

  • 随访8周后,干预组与安慰剂组在母血清PGE2水平上无显著差异。
  • 随访8周后,干预组与安慰剂组在导管血流多普勒超声心动图参数上无显著差异。
  • 研究期间未观察到动脉导管收缩病例。
  • 随孕周进展预期的组内心脏形态学变化存在。

临床应用与阅片要点

  • 作者认为上述发现需在更大样本量的上市后监测研究中确认,以检验DHA的完整安全性特征并提供可靠的临床 reassurance。

局限性

  • 作者指出这些发现需在更大样本量的上市后监测研究中确认,以检验DHA的完整安全性特征并提供可靠的临床 reassurance。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Docosahexaenoic acid (DHA) is recommended routinely in pregnancy to promote fetal development. DHA has anti-inflammatory activity, but its effects on the fetal heart and circulation are unknown. This study aimed to investigate whether maternal DHA supplementation in the third trimester affects maternal prostaglandin levels and fetal ductus arteriosus flow dynamics.

METHODS: This was a double-blind randomized controlled trial with parallel groups conducted between 2018 and 2021. Pregnant women aged over 18 years with a normal fetus at 27-28 weeks' gestation showing no cardiac/extracardiac anomalies or ductal constriction were eligible for the trial. Women consuming substances with a known inhibitory effect on prostaglandin metabolism, such as non-steroidal anti-inflammatory drugs and polyphenol-rich foods, were excluded. The intervention group received oral supplementation of omega-3 with 450 mg/day of DHA for 8 weeks and the placebo group received capsules of soy lecithin for 8 weeks. Anthropometric measurements, assessment of polyphenol and omega-3 consumption, fetal morphological ultrasound examination, fetal Doppler echocardiographic examination and blood sample collection were performed at the start of the study and the latter two were repeated at follow-up. Prostaglandin E2 (PGE2) level and echocardiographic parameters were compared between the intervention and placebo groups and between baseline and follow-up.

RESULTS: A total of 24 participants were included in each group. After 8 weeks, there were no significant differences between the intervention and placebo groups in maternal serum PGE2 level or Doppler echocardiographic parameters of ductal flow. No case of ductus arteriosus constriction was observed. The expected intragroup changes in cardiac morphology, as a result of advancing gestation, were present.

CONCLUSIONS: Maternal DHA supplementation in the third trimester at a clinically recommended dose did not result in inhibition of PGE2 or constriction of the ductus arteriosus. These findings should be confirmed in postmarket surveillance studies with larger patient numbers in order to test the full safety profile of DHA and provide robust clinical reassurance. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zielinsky P, Alves DR, Foresti JDÁ, et al. Maternal supplementation with docosahexaenoic acid does not cause constriction of fetal ductus arteriosus: randomized controlled trial. Ultrasound Obstet Gynecol. 2024. PMID: 38214544. doi:10.1002/uog.27584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。